文献速递肿瘤 PET/CT

68Ga-PSMA-11 PET/CT对生化复发前列腺癌患者管理的影响

Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence.
PubMed 文献 · J Nucl Med · 2017-12-14

这项前瞻性调查纳入161例生化复发前列腺癌患者,由转诊医生在扫描前后填写问卷。101例有完整管理记录者中,54例(53%)实际实施的管理较扫描前计划发生改变;扫描后早期意向改变有47%未实施。盆腔淋巴结及远处转移与实施改变显著相关。

要点

  • 68Ga-PSMA-11 PET/CT使53%(54/101)生化复发前列腺癌患者的实际管理发生改变。
  • 扫描后意向管理改变为61%(62/101),但其中47%(29/62)未实际实施。
  • PSMA T0N1M0和T0N1M1模式与实施管理改变显著相关(P=0.001和0.05)。

核心结论

  • 68Ga-PSMA-11 PET/CT信息使超过50%的生化复发前列腺癌患者管理发生改变(54/101;53%)。
  • 然而,扫描后早期意向管理改变常与实际实施的管理改变不同。

研究设计与样本

  • 前瞻性调查(NCT02940262),纳入转诊医生转诊的161例生化复发前列腺癌患者,中位前列腺特异性抗原值1.7 ng/mL(范围0.05-202 ng/mL)。
  • 转诊医生在扫描前填写问卷说明无68Ga-PSMA-11 PET/CT信息时的治疗计划(Q1;n=101),扫描后立即填写问卷说明意向管理改变(Q2;n=101),3-6个月后填写问卷记录最终实施的管理(Q3;n=56)。
  • 实施的管理还通过电子病历回顾或患者联系获取(n=45)。

主要发现

  • 101/161例患者(63%)有完整记录的管理策略(Q1+Q2+实施管理)。
  • 这些患者中76例(75%)68Ga-PSMA-11 PET/CT结果阳性。
  • 101例中54例(53%)实施的管理与扫描前意向管理(Q1)不同。
  • 101例中62例(61%)扫描后意向管理(Q2)与扫描前意向管理(Q1)不同,但其中29/62例(47%)意向改变未实施。
  • 68Ga-PSMA-11 PET/CT显示盆腔淋巴结和远处转移病变(PSMA T0N1M0和PSMA T0N1M1模式)与实施的管理改变显著相关(P=0.001和0.05)。

关键数值与推荐

  • 完整记录管理策略的患者比例为63%(101/161)。
  • 68Ga-PSMA-11 PET/CT阳性率为75%(76/101)。
  • 实施管理与扫描前意向管理不同的比例为53%(54/101)。
  • 扫描后意向管理与扫描前意向管理不同的比例为61%(62/101),其中未实施比例为47%(29/62)。
  • PSMA T0N1M0模式与实施管理改变相关P=0.001,PSMA T0N1M1模式相关P=0.05。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In this prospective survey of referring physicians, we investigated whether and how 68Ga-labeled prostate-specific membrane antigen 11 (68Ga-PSMA-11) PET/CT affects the implemented management of prostate cancer patients with biochemical recurrence (BCR). Methods: We conducted a prospective survey of physicians (NCT02940262) who referred 161 patients with prostate cancer BCR (median prostate-specific antigen value, 1.7 ng/mL; range, 0.05-202 ng/mL). Referring physicians completed one questionnaire before the scan to indicate the treatment plan without 68Ga-PSMA-11 PET/CT information (Q1; n = 101), one immediately after the scan to denote intended management changes (Q2; n = 101), and one 3-6 mo later to document the final implemented management (Q3; n = 56). The implemented management was also obtained via electronic chart review or patient contact (n = 45). Results: A complete documented management strategy (Q1 + Q2 + implemented management) was available for 101 of 161 patients (63%). Seventy-six of these (75%) had a positive 68Ga-PSMA-11 PET/CT result. The implemented management differed from the prescan intended management (Q1) in 54 of 101 patients (53%). The postscan intended management (Q2) differed from the prescan intended management (Q1) in 62 of 101 patients (61%); however, these intended changes were not implemented in 29 of 62 patients (47%). Pelvic nodal and extrapelvic metastatic disease on 68Ga-PSMA-11 PET/CT (PSMA T0N1M0 and PSMA T0N1M1 patterns) was significantly associated with implemented management changes (P = 0.001 and 0.05). Conclusion: Information from 68Ga-PSMA-11 PET/CT brings about management changes in more than 50% of prostate cancer patients with BCR (54/101; 53%). However, intended management changes early after 68Ga-PSMA-11 PET/CT frequently differ from implemented management changes.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Calais J, Fendler WP, Eiber M, et al. Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence. J Nucl Med. 2017. PMID: 29242398. doi:10.2967/jnumed.117.202945

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。